Abstract
RNA interference (RNAi) is an endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. Since its discovery RNAi has become the most widely used experimental tool providing powerful and sequence-specific knockdown of protein expression to elucidate the function of genes. The possibility of blocking the expression of any protein carries huge expectations for potential therapeutic applications in a wide range of diseases. For clinical development, however, the use of RNAi-based therapeutics has to overcome major drawbacks and disadvantages, mainly targeted delivery and safety issues. This review summarizes the current status of progress made in the development of efficient in vivo silencing; focusing on both viral and non viral delivery strategies, and provides an overview of specifications for anti-inflammatory RNAi-based gene therapy in preclinical models of immune- mediated inflammatory disorders such as rheumatoid arthritis, skin disorders and inflammatory bowel diseases.
Keywords: RNA interference, gene therapy, inflammation, nanoparticles, immunotherapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Volume: 9 Issue: 3
Author(s): Gabriel Courties, Jessy Presumey, Isabelle Duroux-Richard, Christian Jorgensen and Florence Apparailly
Affiliation:
Keywords: RNA interference, gene therapy, inflammation, nanoparticles, immunotherapy
Abstract: RNA interference (RNAi) is an endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. Since its discovery RNAi has become the most widely used experimental tool providing powerful and sequence-specific knockdown of protein expression to elucidate the function of genes. The possibility of blocking the expression of any protein carries huge expectations for potential therapeutic applications in a wide range of diseases. For clinical development, however, the use of RNAi-based therapeutics has to overcome major drawbacks and disadvantages, mainly targeted delivery and safety issues. This review summarizes the current status of progress made in the development of efficient in vivo silencing; focusing on both viral and non viral delivery strategies, and provides an overview of specifications for anti-inflammatory RNAi-based gene therapy in preclinical models of immune- mediated inflammatory disorders such as rheumatoid arthritis, skin disorders and inflammatory bowel diseases.
Export Options
About this article
Cite this article as:
Courties Gabriel, Presumey Jessy, Duroux-Richard Isabelle, Jorgensen Christian and Apparailly Florence, Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (3) . https://dx.doi.org/10.2174/1871523011009030251
DOI https://dx.doi.org/10.2174/1871523011009030251 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prostanoid Receptors as Possible Targets for Anti-Allergic Drugs: Recent Advances in Prostanoids on Allergy and Immunology
Current Drug Targets Phospholipid/Bile Salt Based Novel Mixed Nanomicelles of Methotrexate Co-encapsulated with Sesamol: Preparation, Characterization, and Evaluation of Antiradical Effects In Vitro
Current Nanomedicine Immunological Aspects of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Role of Inflammatory Cells and Toll-Like Receptors in Atherosclerosis
Current Vascular Pharmacology The TOLL-like / Type-I Interferon Pathways as Emerging Therapeutic Targets for Autoimmune Diseases
Drug Design Reviews - Online (Discontinued) Formation Mechanism of Insulin Fibrils and Structural Aspects of the Insulin Fibrillation Process
Current Protein & Peptide Science Human Eosinophils - Potential Pharmacological Model Applied in Human Histamine H<sub>4</sub> Receptor Research
Current Medicinal Chemistry Recent Advances in the Design and Synthesis of Small Molecule Carbonic Anhydrase IX Inhibitors
Current Topics in Medicinal Chemistry Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Current Alzheimer Research Role of IL-17F in the Pathogenesis of Psoriasis
Current Immunology Reviews (Discontinued) Pulmonary Infections in the Era of Biological Agents
Current Respiratory Medicine Reviews Host Neuro- Immuno-Endocrine Responses In Periodontal Disease
Current Pharmaceutical Design Advanced Glycation End Products as Environmental Risk Factors for the Development of Type 1 Diabetes
Current Drug Targets Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science HDL Therapy: Two Kinds of Right?
Current Pharmaceutical Design Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations
Current Molecular Medicine The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Monocyclic and Fused Azines and Azoles as Histamine H<sub>4</sub> Receptor Ligands
Current Medicinal Chemistry The Capability to Forecast Response to Therapy with Regard to The Time and Intensity of The Inflammatory Process in vitro in Dermal Fibroblasts Induced by IL-12
Current Pharmaceutical Biotechnology Current Status of SUMOylation Inhibitors
Current Medicinal Chemistry